- health
FDA Clears Quantum BioPharma’s Lucid-MS to Proceed to Phase 2 Clinical
- August 11, 2026
- Editorial Feature
Quantum BioPharma (NASDAQ: QNTM) has announced that the FDA has approved the company's Investigational New Drug application for Lucid-MS, its patented first-in-class multiple sclerosis drug candidate — clearing the way for the company to begin its planned Phase 2 clinical trial in patients with progressive MS.
And the company that holds the worldwide patent trades for under $5 a share...
The molecule at the center of Quantum BioPharma’s lead drug candidate, Lucid-MS, was discovered at the University Health Network in Toronto2 — the same institution that gave the world insulin3 and stem cell research.4
The company holds worldwide exclusive patent rights through the mid-2030s.5
The FDA’s decision means the agency has reviewed and approved Quantum BioPharma’s application to begin human clinical trials of Lucid-MS in MS patients.
That is not the same as approving Lucid-MS as a treatment for multiple sclerosis. The drug has not been approved to treat MS. Efficacy in MS patients has not been established.
This is significant, however, because nearly 2.8 million6 people worldwide are living with multiple sclerosis. Virtually every approved drug for the disease works by suppressing the immune system.7
Existing therapies may slow progression for some patients8, but don’t repair the neurological damage MS causes.
In contrast, Lucid-MS is being investigated for its potential to protect myelin and address neurodegeneration.
Development-stage biotech carries substantial risk. Most drugs that enter clinical trials never reach patients.
But for investors who follow this sector, the period after animal studies, after Phase 1 safety testing, and after FDA clearance to proceed into Phase 2 has historically been a moment that attracts serious attention. There is no assurance that will prove true here.
Twenty Approved Drugs, None Stop the Disease
Lucid-MS works on an entirely different principle than today’s MS drugs.
Instead of suppressing the immune system, it’s designed to protect the myelin sheath itself – the “insulation” around nerve fibers that MS destroys.
In laboratory animal tests, treatment with Lucid‑MS led to significant improvement, with test subjects regaining normal movement and near‑complete functional recovery in company‑reported preclinical studies.10
The significance of these preclinical findings, and whether they will translate to humans, remain uncertain.
The Global MS Market Is Projected to Reach $43.9 Billion by 2033
The global market for MS therapeutics is currently valued at approximately $25.9 billion annually — and is projected to reach $43.9 billion by 2033.11
A commercialization consultant retained by Quantum BioPharma (NASDAQ: QNTM) projects peak annual sales, if Lucid-MS reaches market, of up to $5 billion.12 This is for a company currently valued at only $28 million and selling for under $5 per share.
What’s more, Quantum BioPharma has announced that the FDA has approved its Investigational New Drug (IND) application for Lucid-MS, allowing the company to proceed with its planned Phase 2 clinical trial. The Phase 2 trial is designed to be the very first time people living with MS would be tested to observe if the results previously seen in animals are replicated in human trials.
Suppressing the Immune System Slows MS. It Does Not Stop It.
Years ago, researchers trying to treat MS focused on suppressing the immune attack on the myelin “insulation” around nerve fibers. More than twenty disease-modifying therapies have been approved on this basis.
These therapies can work, but up to a point. They slow the frequency of relapses in some patients. But they do not stop the disease or repair existing damage.
Plus, suppressing the immune system can create significant side effects, such as increased risk of infection and potential liver toxicity.
Some effects are severe enough that patients discontinue treatment entirely and unfortunately, for some, current treatments do not work at all.
The Worst-Affected Patients Have the Fewest Options
There’s another problem with existing MS therapies that receives less attention than it deserves.
The drugs that exist were designed largely for relapsing-remitting MS — the form of the disease in which symptoms flare and then partially subside.
For patients with progressive MS, in which the deterioration is continuous and irreversible, existing treatment options are minimal.
The most severely affected patients have the fewest choices.
What MS Research May Have Overlooked
For decades, the scientific consensus held that MS is primarily an autoimmune disease.
The theory was that the immune system attacks myelin without provocation.
The alternative theory holds that something happens to the myelin first — subtle molecular changes that the immune system then mistakes for a foreign agent and attacks.
The goal is to stop the myelin degradation that triggers the immune attack.
This is fundamentally different from suppressing the immune response after the fact.
Paralyzed Animal Test Subjects Walked Again - No Approved MS Drug Has Ever Done That
In preclinical animal tests, the results were striking.
Test subjects with MS-like symptoms — including leg paralysis — were treated with Lucid-MS. Full functional recovery was observed. The test subjects walked and moved normally again.21
No disease-modifying therapy currently on the market has produced functional recovery in this way. And that distinction matters enormously.
The body’s own repair mechanisms operate continuously in MS patients. But they are overwhelmed by the ongoing damage. The new Lucid-MS treatment may allow them to “catch up.”
Lucid-MS is something known as a “New Chemical Entity.” It’s patented but has never previously been administered to a human being until Quantum BioPharma’s (NASDAQ: QNTM) Phase 1 trials were completed. The Phase 1 trial showed that Lucid-MS had no major reported side effects in the healthy people who tested it.
It was discovered at the University Health Network. UHN comprises the University of Toronto, five major hospitals, and the Krembil Brain Institute.
Phase 1 Is Complete. FDA Clears Lucid-MS to Proceed to Phase 2.
Taking a molecule from laboratory models to a clinical program in human patients is a long and demanding process, and Quantum BioPharma (NASDAQ: QNTM) has been moving through it methodically.
Phase 1 clinical trials are designed to test safety and tolerability in healthy people, not to measure efficacy in MS patients.
Lucid‑MS has completed its first‑in‑human clinical trial, with the experimental molecule administered for the first time to healthy volunteers as part of a Phase 1 study.24
After a 15,000-Page Submission, FDA Clears Lucid-MS to Proceed to Phase 2
The FDA has approved the company’s Investigational New Drug application, enabling Quantum BioPharma to immediately advance its patented, first-in-class multiple sclerosis program into Phase 2 clinical development.
The IND submission comprised approximately 15,000 pages, and the company subsequently responded to FDA comments. The FDA has approved the IND, allowing the planned Phase 2 study to proceed.25
With FDA approval of the IND now received, Quantum BioPharma has crossed a key regulatory milestone toward Phase 2 initiation. Trial start-up activities, including site selection, are already underway, and the Company expects to initiate patient enrollment and drug administration as quickly as possible. Before it begins, the company is largely invisible to the funds and analysts that move markets.
Going Where No Other MS Trial Is Going
The FDA-authorized Phase 2 protocol is expected to involve patients across sites in the United States, Canada, and Europe, and to run approximately 12 months. And it contains a detail that distinguishes it from most other MS clinical trials currently underway: it plans to recruit patients with progressive MS.
Progressive MS patients are those whose disease is advancing continuously without periods of remission. They are being left out.
Quantum BioPharma (NASDAQ: QNTM) plans to recruit them. Not because it’s easier. Because if Lucid-MS works for the patients nobody else is treating, there is limited competition for the market it enters.
In parallel, the company is conducting a joint imaging study with scientists at Massachusetts General Hospital. The study uses positron emission tomography (PET) scans to measure myelin density changes in patients over time. It will generate independent data to strengthen the Phase 2 evidence base.26
Massachusetts General Hospital is a principal teaching hospital of Harvard Medical School and among the most cited research institutions in the world.
Its involvement generates independent third-party data on myelin density changes — data that neither Quantum BioPharma nor its hired consultants produce. That independence matters to regulators and to investors alike.
A Potential Shortcut Through the FDA — If the Data Supports It
The FDA has established pathways — including accelerated approval — that may, under certain circumstances, allow conditional market access before a full Phase 3 program is complete. These pathways are discretionary.
They require FDA agreement on acceptable endpoints, and any company granted accelerated approval must complete confirmatory studies.
The FDA has not indicated whether Lucid-MS would qualify for accelerated approval.
Any such determination would depend entirely on clinical results and regulatory review.
The commercialization assessment commissioned by Quantum BioPharma specifically contemplates this possibility.27
If that pathway were applicable — and there is no assurance it would be — it could hypothetically compress what is typically a multi-year drug development timeline. That remains speculative until Phase 2 data exists and FDA engages on the question.
FDA approval of the IND application does not mean FDA has approved Lucid-MS as a treatment for MS, endorsed an accelerated approval pathway, agreed the drug works, or indicated eventual marketing approval.
The Scientists Behind the Drug Are Not Typical for a Company This Size
For a company with a market cap of $28 million, the scientific and clinical team assembled around Lucid-MS is unusual.
Dr. Lakshmi Kotra is the co-inventor of the Lucid-MS patent. He is a Senior Scientist at the Krembil Brain Institute, a Professor of Medicinal Chemistry at the University of Toronto and the recipient of the Julia Levy Award — an honor given to only eleven people since the award’s inception in 2008, recognizing scientists who have made exceptional contributions to the commercialization of Canadian biomedical innovation.29
Dr. Andrzej Chruscinski holds both an MD and a PhD from Stanford University. He completed fellowships in cardiology at Stanford and Toronto General and has led two major clinical trials. He serves as Vice President of Clinical and Scientific Affairs.
Investors who have watched development-stage drug programs succeed and fail know that execution at the clinical stage — the quality of the protocol, the rigor of the enrollment, the credibility of the data is where drugs are won and lost.
What Investors Should Know Before They Decide
Quantum BioPharma (NASDAQ: QNTM) is a development-stage specialty biopharmaceutical company headquartered in Toronto.
In addition to Lucid-MS, Quantum BioPharma holds an approximately 20% equity stake in Unbuzzd Wellness Inc. and receives a 7% royalty on all unbuzzd™ sales. Unbuzzd™ is a commercially launched alcohol recovery beverage available through e-commerce and expanding retail distribution. Quantum BioPharma carries none of the manufacturing, distribution, or marketing costs.
The company’s own investor materials include extensive cautionary language about execution risk, regulatory risk, capital markets risk, and the possibility of losing invested capital entirely. Investors considering a position should read those disclosures carefully and consult their own financial advisors before making any investment decision.
For investors who understand what development-stage biotech carries — and who recognize the specific combination of factors that has historically preceded significant value creation in this sector — Quantum BioPharma (NASDAQ: QNTM) trades at approximately $5 per share.
What Is Not Uncertain Is Where This Company Stands Today
Development-stage biotech investing is not for everyone. The risks are real, the timelines are uncertain, and the FDA has the final word. Quantum BioPharma’s (NASDAQ: QNTM) own disclosures make that clear.
But the combination sitting inside this company — a first-in-class molecule from the institution that gave the world insulin, a Stanford-trained clinical team, a Phase 2 trial targeting the MS patients few others are treating, and a commercialization assessment projecting up to $5 billion in potential peak annual sales — is not a combination that investors in this sector encounter often.
The investor relations page and all public filings are available at www.quantumbiopharma.com.
6 Things to Know About Quantum BioPharma and Lucid-MS
- Lucid-MS uses a potentially different mechanism from every approved MS drug on the market. Whether it will prove effective in humans has not yet been established.
- The molecule was discovered at the University Health Network in Toronto — the institution that gave the world insulin. The co-inventor of the patent remains actively involved in the program.
- The Phase 2 trial is designed to recruit progressive MS patients — a population with few existing treatment options and one that most other MS clinical trials are not targeting.
- Phase 1 was completed with no major side effects reported in healthy volunteers. Following an IND submission comprising approximately 15,000 pages, the FDA has approved the company’s IND application, enabling it to proceed with its planned Phase 2 clinical trial of Lucid-MS.
- A commercialization firm commissioned by Quantum BioPharma projects peak annual sales of up to $5 billion if the drug reaches market. These are projections only. There is no assurance Lucid-MS will ever reach the market.
- Development-stage biotech investments carry the risk of total loss. Investors should read the company’s full risk disclosures and consult their own financial advisors before making any investment decision.
Quantum BioPharma (NASDAQ: QNTM) trades at under $5 per share. Public filings are available at www.quantumbiopharma.com.
An FDA-authorized Phase 2 MS drug candidate and a consumer beverage launch — the thesis behind QNTM.
IMPORTANT NOTICE AND DISCLAIMER
This communication is a paid advertisement and investor relations communication. Think Ink Marketing and its owners, managers, employees, and assigns (collectively, the “Publisher”) are often paid by profiled companies or third parties to organize marketing campaigns, including the creation and dissemination of investor awareness communications such as this.
In this case, in an effort to enhance public awareness through an investor awareness campaign for Quantum BioPharma Ltd. (NASDAQ: QNTM) (“Quantum BioPharma” or “QNTM”) and its securities, Think Ink Marketing has been engaged by FinnCom, Inc. (“Sponsor”) on behalf of QNTM. Think Ink Marketing has been paid by FinnCom, Inc. in cash compensation of up to $25,000 USD per month for investor relations and investor awareness services related to QNTM. No stock or other securities have been received as compensation unless separately disclosed. Think Ink Marketing retains remaining funds after expenses as profit.
This compensation should be viewed as a major conflict with the Publisher’s ability to be unbiased. Readers and viewers should be aware that third parties, profiled companies, and/or their affiliates may sell or liquidate shares of QNTM at any time, including at or near the time you receive or view this communication, which could negatively impact share prices. Securities featured in investor awareness campaigns may experience increased trading volume and price volatility during the campaign period, which may decline significantly once the campaign ends.
No price targets or specific investment recommendations are provided by the Publisher.
This communication is for informational and advertising purposes only and should not be construed as an offer to sell or a solicitation of an offer to buy any security. Neither this communication nor the Publisher provides a complete analysis of Quantum BioPharma Ltd. or its financial position. The Publisher is not a registered broker-dealer or investment adviser. This communication is not personalized investment advice and should not be relied upon as such. Investors should consult a licensed financial advisor and review all available public filings, including those filed with the U.S. Securities and Exchange Commission, before making any investment decision.
Investing in securities, particularly small-cap and development-stage biotechnology securities, is speculative and involves a high degree of risk. Past performance is not indicative of future results.
This communication is based on publicly available information and, where applicable, company-provided information or interviews with company management. To the Publisher’s knowledge, this communication does not contain material non-public information. While the information is believed to be reliable, the Publisher makes no representation or warranty as to its accuracy or completeness.
SHARE OWNERSHIP
The Publisher does not own any shares of QNTM unless separately disclosed. The Publisher has no information regarding share ownership by third parties. The Publisher cautions that third parties, including affiliates of the company, may buy or sell shares at any time, which may impact the market price of the securities.
FORWARD-LOOKING STATEMENTS
This communication may contain forward-looking statements, including statements regarding business plans, clinical development, product candidates, market opportunities, regulatory milestones, commercialization potential, future performance, and other expectations regarding QNTM. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially.
Forward-looking statements are based on management’s current expectations, estimates, and assumptions, including but not limited to assumptions regarding clinical trial results, regulatory approvals, capital availability, market conditions, operational execution, competitive landscape, intellectual property protection, and economic stability. These assumptions may prove to be incorrect.
Risks include, but are not limited to: clinical trial risk, regulatory risk, financing risk, market volatility, operational challenges, competition, dilution, changes in applicable laws or regulations, and other risks disclosed in the company’s public filings.
Except as required by law, the Publisher undertakes no obligation to update forward-looking statements.
INDEMNIFICATION / RELEASE OF LIABILITY
By reading, watching, or otherwise accessing this communication, you acknowledge that you have read and understood this disclaimer and agree that the Publisher, its affiliates, and assigns shall not be liable for any damages or losses arising from your reliance on this information. You are solely responsible for your investment decisions.
INTELLECTUAL PROPERTY
Think Ink Marketing is a trademark of the Publisher. Quantum BioPharma, QNTM, and any other third-party trademarks are the property of their respective owners. The Publisher is not affiliated with, endorsed by, or sponsored by any third-party trademark holders unless explicitly stated.
LUCID-MS / CLINICAL-STAGE BIOPHARMA DISCLOSURE
Lucid-MS, also known as Lucid-21-302, is an investigational drug candidate. Lucid-MS has not been approved by the U.S. Food and Drug Administration, Health Canada, or any other regulatory authority for the treatment of multiple sclerosis or any other disease or condition. Its safety and efficacy have not been established.
Any statements regarding Lucid-MS, including statements regarding its mechanism of action, potential effect on demyelination, preclinical results, Phase 1 results, regulatory pathway, clinical development plans, or commercial potential, are based on publicly available company disclosures and should not be interpreted as medical claims, treatment recommendations, or evidence that Lucid-MS will be approved, commercialized, or successfully treat any disease.
Preclinical results, including animal model data, are preliminary and may not be predictive of results in humans. Phase 1 clinical data are generally designed to evaluate safety, tolerability, pharmacokinetics, and related early-stage measures, and do not establish clinical efficacy for the treatment of multiple sclerosis. Future clinical trials may fail to demonstrate safety, efficacy, statistical significance, regulatory acceptability, or commercial viability.
The U.S. FDA has placed the company’s Investigational New Drug application for Lucid-MS on clinical hold pending the submission of additional information requested by the agency. A clinical hold may delay, limit, or prevent the initiation or continuation of clinical trials. There can be no assurance that the FDA will lift the clinical hold, that any planned Phase 2 trial will begin or be completed, or that Lucid-MS will receive regulatory approval.
This communication is not intended for patients or healthcare decision-making and should not be used as medical advice. Patients should consult licensed healthcare professionals regarding multiple sclerosis or any medical condition.
IMPORTANT NOTICE AND DISCLAIMER
This article is a paid advertisement. Think Ink Marketing and its owners, managers, employees, and assigns (collectively “the Publisher”) is often paid by profiled companies or third parties to organize marketing campaigns, which include the creation and dissemination of these types of communications. In this case, in an effort to enhance public awareness of for Quantum BioPharma (“QNTM”) and its securities, QNTM has provided the Publisher with a budget of approximately $30,000 USD to cover the costs associated with the creation and distribution of this communication. The Publisher may retain any excess sums after expenses as its compensation. This compensation should be viewed as a major conflict with our ability to be unbiased. Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price may likely occur. This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position. The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser. This communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results. This communication is based on information generally QNTMlable to the public and on interviews with company management, and does not (to the Publisher’s knowledge, as confirmed by QNTM) contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher cannot guarantee the accuracy or completeness of the information.
SHARE OWNERSHIP.
The Publisher does not own any shares of QNTM and has no information concerning share ownership by others of in QNTM. The Publisher cautions readers to beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you read the articles on this website and this has the potential to hurt share prices. Frequently companies profiled in such articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases.
FORWARD LOOKING STATEMENTS.
This publication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. The Publisher notes that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect the companies’ actual results of operations. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to QNTM’s industry; (b) market opportunity; (c) QNTM’s business plans and strategies; (d) services that QNTM intends to offer; (e) QNTM’s milestone projections and targets; (f) QNTM’s expectations regarding receipt of approval for regulatory applications; (g) QNTM’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) QNTM’s expectations regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute QNTM’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) QNTM’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) QNTM’s ability to enter into contractual arrangements; (e) the accuracy of budgeted costs and expenditures; (f) QNTM’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption as a result of COVID-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of QNTM to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) QNTM operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as the COVID-19 pandemic may adversely impact QNTM’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing QNTM’s business operations (e) QNTM may be unable to implement its growwth strategy; and (f) increased competition. Except as required by law, the Website Host undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise.
INDEMNIFICATION/RELEASE OF LIABILITY.
By reading this communication, you acknowledge that you have read and understand this disclaimer, and further that to the greatest extent permitted under law, you release the Publisher, its affiliates, assigns and successors from any and all liability, damages, and injury from this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.
INTELLECTUAL PROPERTY.
Think Ink Marketing is the Publisher’s trademark. All other trademarks used in this communication are the property of their respective trademark holders. The Publisher is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks.
IMPORTANT NOTICE AND DISCLAIMER
This website is owned and hosted by Tycona Media Ltd. Articles appearing on this website should be considered paid advertisements. Tycona Media Ltd. and its owners, managers, employees, and assigns (collectively “the Website Host”) is often paid by marketing companies to host websites on which articles profiling public companies are published. The Website Host has not been compensated by any of the profiled companies. The Website Host’s compensation for articles appearing on this website is as follows:
The Website Host has been paid approximately $500 per month while the advertisement campaign is active by Think Ink Marketing as compensation to host the article profiling Quantum BioPharma (“QNTM”).
SHARE OWNERSHIP
The Website Host does not own any shares of any profiled compannies and has no information concerning share ownership by others of any profiled companies. The Website Host cautions readers to beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you read the articles on this website and this has the potential to hurt share prices. Frequently companies profiled in such articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases.
NO SECURITIES OFFERED
The articles on this website are not, and should not be construed to be, offers to sell or solicitations of an offer to buy any security. Neither the articles on this website nor the Website Host purport to provide a complete analysis of QNTM or its financial position. The Website Host is not, and does not purport to be, a broker-dealer or registered investment adviser. The articles on this website are not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about QNTM Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in QNTM’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk.
INDEMNIFICATION/RELEASE OF LIABILITY
By reading articles on this website, you acknowledge that you have read and understood this disclaimer, and further that to the greatest extent permitted under law, you release the Website Host, its affiliates, assigns and successors from any and all liability, damages, and injury from articles appearing on this website. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.
LINKS TO THIRD PARTY WEBSITES
This website enables users to link to external websites not under the control of The Website Host. The Website Host has no control over the nature, content, and QNTM lability of those sites. The inclusion of any links is not intended as, and should not be construed as, a recommendation or endorsement of the content or views expressed on such external websites. The Website Host expressly disclaims any representation concerning the quality, safety, suitability, or reliability of any external websites and the content and materials contained in them. It is important for users to take necessary precautions, especially to ensure appropriate safety.
INTELLECTUAL PROPERTY
The Tomorrow Investor is the Website Host’s trademark. All other trademarks used in this communication are the property of their respective trademark holders. The Website Host is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Website Host to any rights in any third-party trademarks.
FORWARD LOOKING INFORMATION
This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect expectations regarding QNTM’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to QNTM’s industry; (b) market opportunity; (c) QNTM’s business plans and strategies; (d) services that QNTM intends to offer; (e) QNTM’s milestone projections and targets; (f) QNTM’s expectations regarding receipt of approval for regulatory applications; (g) QNTM’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) QNTM’s expectations regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute QNTM’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) QNTM’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) QNTM’s ability to enter into contractual arrangements; (e) the accuracy of budgeted costs and expenditures; (f) QNTM’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption as a result of COVID-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of QNTM to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) QNTM’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as the COVID-19 pandemic may adversely impact QNTM’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing QNTM’s business operations (e) QNTM may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, the Website Host undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise.
HISTORICAL INFORMATION
Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of QNTM or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of QNTM or such entities and are not necessarily indicative of future performance of QNTM or such entities.
COMPANY SPOTLIGHT
LATEST NEWS
Discover the Opportunity Behind Quantum BioPharma
To Your Watch List Today!
